JPWO2021236550A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021236550A5 JPWO2021236550A5 JP2022570108A JP2022570108A JPWO2021236550A5 JP WO2021236550 A5 JPWO2021236550 A5 JP WO2021236550A5 JP 2022570108 A JP2022570108 A JP 2022570108A JP 2022570108 A JP2022570108 A JP 2022570108A JP WO2021236550 A5 JPWO2021236550 A5 JP WO2021236550A5
- Authority
- JP
- Japan
- Prior art keywords
- smva
- seq
- sars
- cov
- shows
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims description 69
- 108090000623 proteins and genes Proteins 0.000 claims description 69
- 102000004169 proteins and genes Human genes 0.000 claims description 65
- 229960005486 vaccine Drugs 0.000 claims description 65
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 39
- 108020004414 DNA Proteins 0.000 claims description 38
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 31
- 208000015181 infectious disease Diseases 0.000 claims description 22
- 238000003780 insertion Methods 0.000 claims description 18
- 230000037431 insertion Effects 0.000 claims description 18
- 108020004705 Codon Proteins 0.000 claims description 17
- 241000700605 Viruses Species 0.000 claims description 14
- 241000711573 Coronaviridae Species 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 101001024637 Severe acute respiratory syndrome coronavirus 2 Nucleoprotein Proteins 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 230000006801 homologous recombination Effects 0.000 claims description 5
- 238000002744 homologous recombination Methods 0.000 claims description 5
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 108091006197 SARS-CoV-2 Nucleocapsid Protein Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 description 109
- 108091007433 antigens Proteins 0.000 description 101
- 102000036639 antigens Human genes 0.000 description 101
- 239000013598 vector Substances 0.000 description 79
- 241001678559 COVID-19 virus Species 0.000 description 70
- 101710137302 Surface antigen S Proteins 0.000 description 69
- 210000004027 cell Anatomy 0.000 description 58
- 230000035772 mutation Effects 0.000 description 56
- 235000001014 amino acid Nutrition 0.000 description 54
- 235000018102 proteins Nutrition 0.000 description 54
- 206010046865 Vaccinia virus infection Diseases 0.000 description 50
- 208000007089 vaccinia Diseases 0.000 description 50
- 241000699670 Mus sp. Species 0.000 description 43
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 42
- 230000014509 gene expression Effects 0.000 description 40
- 108700026244 Open Reading Frames Proteins 0.000 description 39
- 101710139375 Corneodesmosin Proteins 0.000 description 35
- 102100031673 Corneodesmosin Human genes 0.000 description 34
- 210000004899 c-terminal region Anatomy 0.000 description 28
- 238000002649 immunization Methods 0.000 description 28
- 108090000765 processed proteins & peptides Proteins 0.000 description 28
- 238000006467 substitution reaction Methods 0.000 description 28
- 108010076504 Protein Sorting Signals Proteins 0.000 description 27
- 102220599406 Spindlin-1_N501Y_mutation Human genes 0.000 description 26
- 230000027455 binding Effects 0.000 description 26
- 230000003053 immunization Effects 0.000 description 26
- 101710141454 Nucleoprotein Proteins 0.000 description 24
- 102220114694 rs763810935 Human genes 0.000 description 24
- 238000000034 method Methods 0.000 description 23
- 230000004044 response Effects 0.000 description 23
- 125000000539 amino acid group Chemical group 0.000 description 20
- 230000006798 recombination Effects 0.000 description 20
- 238000005215 recombination Methods 0.000 description 20
- 241000700662 Fowlpox virus Species 0.000 description 18
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 150000001413 amino acids Chemical group 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 230000005867 T cell response Effects 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 238000012217 deletion Methods 0.000 description 15
- 230000037430 deletion Effects 0.000 description 15
- 235000013930 proline Nutrition 0.000 description 15
- 241000699800 Cricetinae Species 0.000 description 14
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 108090000978 Interleukin-4 Proteins 0.000 description 13
- 102000004388 Interleukin-4 Human genes 0.000 description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 13
- 239000004472 Lysine Substances 0.000 description 13
- 230000003472 neutralizing effect Effects 0.000 description 13
- 238000001543 one-way ANOVA Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- -1 subunits thereof Substances 0.000 description 13
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 11
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 11
- 230000009870 specific binding Effects 0.000 description 11
- 239000004474 valine Substances 0.000 description 11
- 239000004475 Arginine Substances 0.000 description 10
- 102000004961 Furin Human genes 0.000 description 10
- 108090001126 Furin Proteins 0.000 description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 10
- 238000003776 cleavage reaction Methods 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 230000007017 scission Effects 0.000 description 10
- 238000011740 C57BL/6 mouse Methods 0.000 description 9
- 108010067902 Peptide Library Proteins 0.000 description 9
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 9
- 238000006386 neutralization reaction Methods 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 102220057653 rs587780059 Human genes 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 241000282552 Chlorocebus aethiops Species 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241001112090 Pseudovirus Species 0.000 description 8
- 102000044437 S1 domains Human genes 0.000 description 8
- 108700036684 S1 domains Proteins 0.000 description 8
- 241000315672 SARS coronavirus Species 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 230000028996 humoral immune response Effects 0.000 description 8
- 230000003248 secreting effect Effects 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 238000010162 Tukey test Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 210000004988 splenocyte Anatomy 0.000 description 7
- 102100034013 Gamma-glutamyl phosphate reductase Human genes 0.000 description 6
- 101001133924 Homo sapiens Gamma-glutamyl phosphate reductase Proteins 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 102220590628 Spindlin-1_L18F_mutation Human genes 0.000 description 6
- 102220599629 Spindlin-1_Q1071H_mutation Human genes 0.000 description 6
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- 230000036755 cellular response Effects 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102200056390 rs12204826 Human genes 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108010008038 Synthetic Vaccines Proteins 0.000 description 5
- 229940037003 alum Drugs 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 229940124551 recombinant vaccine Drugs 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 102220579649 ATP-dependent RNA helicase A_K417N_mutation Human genes 0.000 description 4
- 241000008904 Betacoronavirus Species 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 102220599680 Spindlin-1_A570D_mutation Human genes 0.000 description 4
- 102220599400 Spindlin-1_D1118H_mutation Human genes 0.000 description 4
- 102220590324 Spindlin-1_D80A_mutation Human genes 0.000 description 4
- 102220590625 Spindlin-1_P26S_mutation Human genes 0.000 description 4
- 102220599630 Spindlin-1_T1027I_mutation Human genes 0.000 description 4
- 102220590630 Spindlin-1_T20N_mutation Human genes 0.000 description 4
- 102220599418 Spindlin-1_V1176F_mutation Human genes 0.000 description 4
- 102220510809 Toll-like receptor 3_P681H_mutation Human genes 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 102220429344 c.456G>T Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229960005091 chloramphenicol Drugs 0.000 description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 230000008348 humoral response Effects 0.000 description 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 102220277108 rs1553412687 Human genes 0.000 description 4
- 102200144284 rs235768 Human genes 0.000 description 4
- 102220046173 rs587782706 Human genes 0.000 description 4
- 102220046286 rs587782805 Human genes 0.000 description 4
- 102220033185 rs62646881 Human genes 0.000 description 4
- 102220058675 rs786203529 Human genes 0.000 description 4
- 102220029076 rs78775072 Human genes 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 3
- 102220585969 Claspin_S982A_mutation Human genes 0.000 description 3
- 102100030011 Endoribonuclease Human genes 0.000 description 3
- 108010093099 Endoribonucleases Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102210009883 HLA-B*07:02 Human genes 0.000 description 3
- 101000619564 Homo sapiens Putative testis-specific prion protein Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 238000010222 PCR analysis Methods 0.000 description 3
- 101800004803 Papain-like protease Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100022208 Putative testis-specific prion protein Human genes 0.000 description 3
- 102220590680 Spindlin-1_S13I_mutation Human genes 0.000 description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000011808 rodent model Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 102220542981 Ankyrin-1_R21T_mutation Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 238000011510 Elispot assay Methods 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102220543270 Eukaryotic peptide chain release factor GTP-binding subunit ERF3A_Y453F_mutation Human genes 0.000 description 2
- 108010078301 HLA-B*07:02 antigen Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical group OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 241000282341 Mustela putorius furo Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 101710198474 Spike protein Proteins 0.000 description 2
- 102220599627 Spindlin-1_D950N_mutation Human genes 0.000 description 2
- 102220592169 Spindlin-1_E154K_mutation Human genes 0.000 description 2
- 102220590696 Spindlin-1_G142D_mutation Human genes 0.000 description 2
- 102220590621 Spindlin-1_T19R_mutation Human genes 0.000 description 2
- 102220590684 Spindlin-1_T95I_mutation Human genes 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000010219 correlation analysis Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000004201 immune sera Anatomy 0.000 description 2
- 229940042743 immune sera Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 102200137063 rs1446389693 Human genes 0.000 description 2
- 102220053106 rs199537178 Human genes 0.000 description 2
- 102220030033 rs398123766 Human genes 0.000 description 2
- 102220045931 rs587782500 Human genes 0.000 description 2
- 102220059328 rs786202822 Human genes 0.000 description 2
- 102220074121 rs796052019 Human genes 0.000 description 2
- 102220077512 rs797044926 Human genes 0.000 description 2
- 102200024304 rs886037751 Human genes 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000001944 turbinate Anatomy 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 239000012855 volatile organic compound Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- CNNSWSHYGANWBM-UHFFFAOYSA-N 6-chloro-2,3-dimethylquinoxaline Chemical compound C1=C(Cl)C=C2N=C(C)C(C)=NC2=C1 CNNSWSHYGANWBM-UHFFFAOYSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 241000020089 Atacta Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 229940022962 COVID-19 vaccine Drugs 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101100175482 Glycine max CG-3 gene Proteins 0.000 description 1
- 102210024302 HLA-B*0702 Human genes 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 108010071384 Peptide T Proteins 0.000 description 1
- 241001144416 Picornavirales Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 108091006619 SLC11A1 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102220599612 Spindlin-1_A701V_mutation Human genes 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 101150054399 ace2 gene Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 102220350713 c.38C>T Human genes 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010226 confocal imaging Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010569 immunofluorescence imaging Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000002962 plaque-reduction assay Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 102220031793 rs431825282 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063026127P | 2020-05-17 | 2020-05-17 | |
| US63/026,127 | 2020-05-17 | ||
| US202063044033P | 2020-06-25 | 2020-06-25 | |
| US63/044,033 | 2020-06-25 | ||
| US202063113810P | 2020-11-13 | 2020-11-13 | |
| US63/113,810 | 2020-11-13 | ||
| US202163161371P | 2021-03-15 | 2021-03-15 | |
| US63/161,371 | 2021-03-15 | ||
| PCT/US2021/032821 WO2021236550A1 (fr) | 2020-05-17 | 2021-05-17 | Vaccins contre le coronavirus à base de virus de la vaccine ankara modifiée synthétique (smva) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526073A JP2023526073A (ja) | 2023-06-20 |
| JPWO2021236550A5 true JPWO2021236550A5 (fr) | 2024-05-24 |
Family
ID=78708032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570108A Pending JP2023526073A (ja) | 2020-05-17 | 2021-05-17 | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230323389A1 (fr) |
| EP (1) | EP4153228A4 (fr) |
| JP (1) | JP2023526073A (fr) |
| KR (1) | KR20230012583A (fr) |
| CN (1) | CN116348132A (fr) |
| AU (1) | AU2021276265A1 (fr) |
| BR (1) | BR112022023173A2 (fr) |
| CA (1) | CA3183016A1 (fr) |
| IL (1) | IL298210A (fr) |
| MX (1) | MX2022014387A (fr) |
| WO (1) | WO2021236550A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202330575A (zh) * | 2021-09-29 | 2023-08-01 | 瑞典商斯文斯卡疫苗生產股份有限公司 | 用於治療及預防冠狀病毒之組成物及方法 |
| WO2023092021A1 (fr) * | 2021-11-17 | 2023-05-25 | City Of Hope | Vaccins contre le coronavirus à base de vaccinia ankara modifié synthétique (smva) |
| WO2024020545A1 (fr) * | 2022-07-22 | 2024-01-25 | City Of Hope | Vaccins synthétiques contre la vaccine modifiée ankara pour stimuler l'immunité contre l'orthopoxvirus et la variole simienne |
| EP4316514A1 (fr) * | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Vecteurs à base de mva et leur utilisation comme vaccin contre le sars-cov-2 |
| TW202426045A (zh) * | 2022-10-07 | 2024-07-01 | 高端疫苗生物製劑股份有限公司 | 抗新型冠狀病毒(SARS-CoV-2) Omicron變異株之免疫組合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005016238A2 (fr) * | 2003-05-08 | 2005-02-24 | Duke University | Syndrome respiratoire aigu severe |
| WO2005028634A2 (fr) * | 2003-09-18 | 2005-03-31 | Emory University | Vaccins mva ameliores |
| WO2006071250A2 (fr) * | 2004-04-05 | 2006-07-06 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Fragments solubles de la glycoproteine de spicule de cov-sras |
| EP3045181B1 (fr) * | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | Nouveau vaccin contre le coronavirus du syndrome respiratoire du moyen orient (MERS-CoV) |
-
2021
- 2021-05-17 EP EP21809653.5A patent/EP4153228A4/fr active Pending
- 2021-05-17 WO PCT/US2021/032821 patent/WO2021236550A1/fr active Search and Examination
- 2021-05-17 IL IL298210A patent/IL298210A/en unknown
- 2021-05-17 AU AU2021276265A patent/AU2021276265A1/en active Pending
- 2021-05-17 CA CA3183016A patent/CA3183016A1/fr active Pending
- 2021-05-17 KR KR1020227044240A patent/KR20230012583A/ko active Search and Examination
- 2021-05-17 BR BR112022023173A patent/BR112022023173A2/pt unknown
- 2021-05-17 US US17/999,170 patent/US20230323389A1/en active Pending
- 2021-05-17 CN CN202180059838.6A patent/CN116348132A/zh active Pending
- 2021-05-17 JP JP2022570108A patent/JP2023526073A/ja active Pending
- 2021-05-17 MX MX2022014387A patent/MX2022014387A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017204292B2 (en) | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof | |
| CN107921117B (zh) | Hpv疫苗 | |
| Green et al. | C3d enhancement of neutralizing antibodies to measles hemagglutinin | |
| WO2022077593A1 (fr) | Vaccin contre le coronavirus du sars-cov-2 et son procédé de préparation | |
| US8372963B2 (en) | RSV F-protein and its use | |
| EA012037B1 (ru) | Поливалентные вакцины, содержащие рекомбинантные вирусные векторы | |
| JP2023526073A (ja) | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン | |
| WO2021216743A2 (fr) | Vaccins contre le coronavirus,, compositions et procédés associés | |
| CA2726914A1 (fr) | Vaccin pour la prevention et la therapie d'infections par le vhc | |
| JP2719917B2 (ja) | Ａｉｄｓの原因ウィルスの糖蛋白質、該糖蛋白質の製造方法及びワクチン | |
| Restifo et al. | Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer | |
| US20200299651A1 (en) | Simian adenoviral vectors with two expression cassettes | |
| CN114106115A (zh) | 一种腺病毒载体重组新冠病毒b.1.351变异株疫苗及其应用 | |
| CA2989332A1 (fr) | Compositions de vaccin a enterovirus multivalent et utilisations associees | |
| WO2024008014A1 (fr) | Composition pharmaceutique pour résister à une infection par le sars-cov-2 ou un mutant de celui-ci et médicament combiné associé | |
| JPWO2021236550A5 (fr) | ||
| US20230233670A1 (en) | A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease | |
| WO2023064993A1 (fr) | Polypeptides chimériques de spicule de bêta-coronavirus | |
| JPH09509562A (ja) | 新規なタンパク質／ポリペプチド及びコトランスフェクションプラスミド並びにその組換え生キャリヤー | |
| Paolazzi et al. | Rabies vaccine: Developments employing molecular biology methods | |
| WO2020210611A1 (fr) | Vaccin contre le htlv-1 recombiné | |
| CN117512013A (zh) | 一种重组5型腺病毒载体、制备方法、疫苗及其应用 | |
| WO1995007099A1 (fr) | Vaccin et procede pour sa production | |
| Zubair et al. | Live Recombinant Vaccine Vectors for HPV Antigens Associated with Infection and Malignancy |